|
½ÃÀ庸°í¼
¼±µµ¹°Áú(Lead generation)ÀÇ °¡¼ÓÈ : ´ëµÎµÇ´Â ±â¼ú°ú Àü·«
Accelerating Lead Generation: Emerging technologies and strategies
| ¸®¼Ä¡»ç |
Business Insights |
| ¹ßÇàÀÏ |
2009³â 06¿ù |
»óǰÄÚµå |
90255 |
| ÆäÀÌÁö Á¤º¸ |
161 pages |
| °¡°Ý |
|
|
Business Insights ¿¡¼ 2009³â 06¿ù ¿¡ ¹ßÇàÇÑ ¡¸¼±µµ¹°Áú(Lead generation)ÀÇ °¡¼ÓÈ : ´ëµÎµÇ´Â ±â¼ú°ú Àü·«¡¹ º¸°í¼´Â 161 pages·Î ±¸¼ºµÇ¾î, US $3,835 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.
ÃÖ±Ù ´Ù¼öÀÇ ½Å¾à ¹× »ý¹° Á¦Á¦°¡ R&D ÁöÃâÀÇ Áõ´ë·Î ÀÎÇØ ¾ÈÁ¤µÈ Àΰ¡¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. Á¦¾à ±â¾÷¿¡°Ô ÀÖ¾î ½Å¾à°³¹ß ºñ¿ëÀÇ È¿À²È´Â ÁÖÁÖÀÇ È®½ÇÇÑ Æò°¡¸¦ ¾ò±â À§ÇÑ ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ±×·¯¹Ç·Î ¼±µµ¹°Áú âÃâ ÇÁ·Î¼¼½º¿¡ Ãæ½ÇÇÏ´Â °ÍÀÌ °³¹ß ÈıâÀÇ °í°¡ ÈÇÕ¹° ½ÇÆÐ¸¦ ÇÇÇÏ´Â ¿¼è ÀÔ´Ï´Ù. ÀÓ»ó¿¡ ´Ù´Ù¸¥ ½Å¾à ¼ÒÀçÀÇ Ç°Áú °³¼±À» À§ÇÑ Ãֽбâ¼úÀ» Æò°¡ÇÔ°ú µ¿½Ã¿¡ High Throughput Screening(HTS,°íÈ¿À² °Ë»ö), FBDD, Virtual Screeningµî ½Å¾à ¼±µµ¹°Áú âÃâ¿¡ °ü·ÃµÈ ´Ù¾çÇÑ ¹æ¹ýÀÇ ÀÌÁ¡À» °ËÁõÇÏ¿© ±× Àå·¡¼ºÀ» ÃßÃøÇÑ »ó¼¼ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù. °³¿ä - ¼·Ð
- ¶óÀ̺귯¸® µðÀÚÀÎ, Virtual Screening, FBDD
- »ý¹°ÇÐÀû °Ë»ç¹ýÀÇ ±â¼ú Çõ½Å
- ¼±µµ¹°Áú âÃâ¿¡¼ ADME/Tox
- Á¦¾à¾÷°è¿¡¼ ¼±µµ¹°Áú âÃâ Àü·«
- ¼±µµ¹°Áú âÃâÀÇ R&D ¸ðµ¨, ±â¼ú Çõ½Å, ÇâÈÄ Àü¸Á
Á¦1Àå ¼·Ð - ½Å¾à°³¹ß ÇÁ·Î¼¼½º : ¼±µµ¹°ÁúÀÇ Ã¢ÃâÀ» Á¤ÀÇ
- ¡¸Hit ¾àÁ¦¡¹ÀÇ ¹ß°ß°ú °ËÁõ
- Hit ¾àÁ¦ÀÇ ÃÖÀûÈ
- ¼±µµ¹°ÁúÀÇ ÃÖÀûÈ
- ÀáÀçÀû ¼±µµ¹°ÁúÀÇ ±âÁØ
Á¦2Àå ¶óÀ̺귯¸® µðÀÚÀÎ, Virtual Screening, FBDD - °³¿ä
- ¼·Ð
- Hit ¼±µµ¹°Áú - À¯¸ÁÇÑ ±¸Á¶ÀÇ ¹ß°ß
- High Throughput Screening(HTS)ÀÇ ¹Ì·¡
- FBDD(fragment based drug discovery)
- Virtual Screening
- °á·Ð
Á¦3Àå »ý¹°ÇÐÀû °Ë»ç¹ýÀÇ ±â¼ú Çõ½Å - °³¿ä
- ¼·Ð
- HTS¸¦ °³¼±
- HTS¸¦ À§ÇÑ Ã¼¿Ü °Ë»çÀÇ °³¼±
- ¼±µµ¹°ÁúÀÇ Ã¢Ãâ¿¡¼ »ýü ½ÇÇè
- ¼Òµ¿¹° »ýü À̹Ì¡ ¹× Çö¹Ì°æ¹ý
Á¦4Àå ¼±µµ¹°Áú âÃâ¿¡¼ ADME/Tox - °³¿ä
- ¼·Ð
- ADME Ư¼ºÀ» Æò°¡
- ¼±µµ¹°Áú âÃ⠴ܰ迡¼ÀÇ µ¶¹°ÇÐ
- °á·Ð
Á¦5Àå Á¦¾à¾÷°è¿¡¼ ¼±µµ¹°Áú âÃâ Àü·« - °³¿ä
- ¼·Ð
- ¼±µµ¹°Áú âÃâ ÆÀ
- »ç·Ê ¿¬±¸
- °á·Ð
Á¦6Àå ¼±µµ¹°Áú âÃâÀÇ R&D ¸ðµ¨, ±â¼ú Çõ½Å, ÇâÈÄ Àü¸Á - °³¿ä
- ¼·Ð
- R&D ¸ðµ¨ : ¼±µµ¹°Áú âÃâ¿¡ ´ëÇÑ ¿µÇâ
- ±â¼ú Çõ½Å°ú ¹Ì·¡
- ¼±µµ¹°Áú âÃâÀÇ ÇöÀç »óȲ°ú ¹Ì·¡
PMH
|